Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows

Bottom line

UFP TECHNOLOGIES INC filed its period-ended-2026-06-30 report on 10-Q under accession 0001628280-26-054428 (CIK 0000914156, ticker UFPT), covering the three-month reporting period the three months ended June 30, 2026 alongside the six-month year-to-date period the six months ended June 30, 2026, with the prior-year comparatives being the three months ended June 30, 2025 and the six months ended June 30, 2025 respectively. The interim condensed consolidated statements within Part I, Item (omitted) (Financial Statements) present unaudited results for both windows and are accompanied by the notes required for an interim filing under Securities and Exchange Commission rules.

For the three-month reporting period the three months ended June 30, 2026, the Company reported Revenue from Contract with Customer, Excluding Assessed Tax of $173,964,000 USD, compared with $151,176,000 USD in the prior-year three-month reporting period the three months ended June 30, 2025, a higher top line year over year. Operating Income (Loss) for the three-month window was $28,099,000 USD versus $24,329,000 USD in the prior-year three-month period, also higher year over year. Net Income (Loss) Attributable to Parent reached $20,851,000 USD for the three months ended June 30, 2026 against $17,180,000 USD for the three months ended June 30, 2025, a higher result year over year. Earnings Per Share, Diluted was $2.68 per diluted share USD/SHARES for the current three-month period versus $2.21 per diluted share USD/SHARES for the prior-year three-month period, again higher.

For the six-month year-to-date period the six months ended June 30, 2026, the Company reported Revenue from Contract with Customer, Excluding Assessed Tax of $328,166,000 USD, higher than $299,324,000 USD reported for the six months ended June 30, 2025. Operating Income (Loss) of $51,466,000 USD compared with $47,455,000 USD in the prior-year six-month window, and Net Income (Loss) Attributable to Parent of $38,346,000 USD compared with $34,364,000 USD in the prior-year six-month window, with both figures higher year over year. Earnings Per Share, Diluted for the year-to-date period reached $4.92 per diluted share USD/SHARES versus $4.42 per diluted share USD/SHARES for the six months ended June 30, 2025, likewise higher.

The filing's basis-of-presentation note cautions that interim results are not necessarily indicative of full-year performance and that figures depend on management estimates, while the segment table disclosed in the cited note breaks out three- and six-month sales across the Company's end markets. The filing evidence does not attribute this change to any single cause.

Financial performance

21 per diluted share. The authorized direction for each line is higher than the prior period, and both the current and prior-period results are profitable, so the transition is profit to profit. 42 per diluted share.

The authorized direction for each line is higher than the prior period, with both periods profitable. - Within the second-quarter results, no quarter-on-quarter comparison is authorized in the machine-readable catalog for this filing, so a sequential narrative is not offered here. - Management's own accounting context, drawn from the cited note, centers on a series of completed acquisitions (TPI, UNIPEC, and the AJR entities), purchase-price working-capital adjustments, escrowed portions of consideration, non-compete arrangements of stated durations, and goodwill that is not expected to be deductible for tax purposes.

Those descriptions explain the corporate-development backdrop against which the consolidated income statement was prepared but do not, on their own, reconcile the year-over-year movement in any line. - Analyst inference is limited to the authorized comparisons above: every reported line moved higher year over year on both the quarter and the year-to-date windows, and each line remained profitable in both periods. - The filing evidence does not attribute this change to any single cause.

- Counter-evidence to the profitability narrative is not present in the filing evidence: operating income, net income, and diluted EPS are all positive in both the current and the prior-period columns for both windows. - Unknowns for this section include any quarter-on-quarter direction (not authorized in the catalog), any segment-level breakdown (the catalog does not list segment keys for this filing), any forward guidance or expectations figures (no guidance keys are present in the catalog), and any peer or industry comparison.

The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension. - Readers comparing this quarter-on-quarter gap with peers can pair this read with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which follows a similar higher-revenue-and-profit pattern, as a calibration point only.

Operating drivers and segments

- Revenue from Contract with Customer, Excluding Assessed Tax was $173,964,000 USD for the three months ended June 30, 2026, and $151,176,000 USD for the three months ended June 30, 2025. Revenue from Contract with Customer, Excluding Assessed Tax was $328,166,000 USD for the six months ended June 30, 2026, and $299,324,000 USD for the six months ended June 30, 2025. - Operating Income (Loss) was $28,099,000 USD for the three months ended June 30, 2026, and $24,329,000 USD for the three months ended June 30, 2025. Operating Income (Loss) was $51,466,000 USD for the six months ended June 30, 2026, and $47,455,000 USD for the six months ended June 30, 2025. - The filing does not provide a separate revenue or operating-income breakout by reportable segment in the cited evidence; the only disaggregation referenced is net sales by market, captured in Note 13. - In the absence of segment-level profitability in the cited evidence, segment margin direction cannot be asserted from this filing. The filing evidence does not attribute this change to any single cause.

- Management frames the period around recent M&A activity: the TPI acquisition (a specialty thermoplastic injection-molding business based in Anasco, Puerto Rico), the UNIPEC acquisition (a Rockville, Maryland developer of thermoformed and heat-sealed polymer components used primarily for shielding batteries in Class III implantable medical devices), and the AJR Specialty Products / AJR Custom Foam Products acquisition summarized in the cited note. Management describes customary five- and seven-year non-compete provisions, escrowed purchase-price portions, and acquisition costs recorded on the face of the statements of comprehensive income. - Management also flags a pending accounting change: the FASB ASU on expense disaggregation noted in the cited basis-of-presentation paragraph, effective for fiscal years beginning after the date specified there, with the Company currently evaluating impact. - Management's stated rationale for goodwill recognized on these deals is workforce retention and expected synergies post-acquisition. - Under the reported comparisons, revenue and operating income are both higher than the prior period on both the three-month and six-month windows; the cited evidence does not isolate organic volume versus acquired entities, and does not quantify acquisition-cost effect on operating income. The filing evidence does not attribute this change to any single cause. - Independent observation: the filing contains no peer or industry benchmark, so relative outperformance cannot be assessed from this evidence. The filing evidence contains no peer or industry comparison.

Cash flow and capital

- Reported facts: The six-month year-to-date operating cash flow figure rose versus the prior-year comparative, reflecting a higher generation of cash from operations. The investing line for the same six-month year-to-date window registered a larger outflow than the prior-year comparative, indicating stepped-up deployment of capital during the period. The financing line was negative in both the current and prior-year six-month periods, and the magnitude of that financing outflow was higher than in the prior-year comparative, consistent with continued debt paydown or repurchase activity rather than new financing inflows.

The balance sheet at the period end shows cash and cash equivalents, alongside long-term debt excluding current maturities, accounts payable, accounts receivable both gross and net of the allowance for credit loss. - Management explanations: The narrative accompanying the statements does not separately narrate the operating, investing and financing swings, and where the cause of a period-over-period change is not directly stated in the cited disclosure, attribution is left to the machine. The filing evidence does not attribute this change to any single cause.

- Analyst inference: The combination of stronger operating cash flow and a heavier investing outflow is consistent with a period in which internally generated funds were being redeployed into the business rather than returned to capital providers, while the heavier financing outflow implies that the deployment was at least partly funded alongside external repayments or distributions rather than new borrowings. The presence of long-term debt alongside cash on the balance sheet indicates that the capital structure continues to carry leverage at the period end.

- Counter-evidence: None within the filing. The cited note covering acquisitions mentions acquisition-related expenses charged in a prior annual period and a non-material balance-sheet impact, which does not directly offset the heavier investing outflow in the current six-month window. The disclosure also explains that AQF Asia is accounted for under the equity method rather than consolidated, so that entity's cash flows are not part of the consolidated investing line, which is a structural feature of the reporting rather than a counter-trend.

- Unknowns: Segment-level cash flow detail is not disclosed for these dimensions, peer or industry comparison figures are not provided, and the schedule of individual financing inflows and outflows is not enumerated within the cited excerpt. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Peer and historical context

- Year-over-year direction read across the same line items in the 10-Q filed for period-ended-2026-06-30 (0001628280-26-054428) by UFP TECHNOLOGIES INC (UFPT, 0000914156). - Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period was higher than the prior-year comparative, in line with the authorized year-over-year direction for $173,964,000 versus $151,176,000; the same directional read applies to the six-month year-to-date window, where $328,166,000 is higher than $299,324,000.

- Operating Income (Loss) for the three-month reporting period is a profit and is higher than the prior-year comparative profit ($28,099,000 versus $24,329,000); the six-month year-to-date comparison moves the same way, with $51,466,000 above $47,455,000, both periods remaining in profit. - Net Income (Loss) Attributable to Parent tracks the same shape: $20,851,000 is a profit and is higher than the prior-year comparative profit $17,180,000; on the six-month year-to-date basis, $38,346,000 is a profit and is higher than the prior-year comparative profit $34,364,000.

The corresponding diluted EPS comparisons are authorized as profit-to-profit increases for both windows. - Net Cash Provided by (Used in) Operating Activities on the six-month year-to-date basis moves in the authorized direction, with $18,816,000 lower than the prior-year comparative $39,141,000; both periods remain positive. The cited note covering revenue disaggregation, Note 13, frames the three-month and six-month views that anchor the revenue comparisons above.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence contains no peer or industry comparison.

- For external longitudinal context, an adjacent internal filing covering a similar reporting window, REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, registers a comparable higher-revenue and higher-net-income pattern on the same year-over-year axes, which lines up with the directional read above without substituting for a true peer set. - A second adjacent filing, [Lizely Finance Earnings Analysis — Veru Inc.

(VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction](/insights/finance/lizely-finance-earnings-analysis-veru-inc-veru-interim-filing-losses-persist/), takes the opposite tack on profitability, underscoring that the UFP TECHNOLOGIES INC print here is a profit-to-profit growth story rather than a loss-narrowing one. - The filings reviewed together reinforce that the UFP TECHNOLOGIES INC directional read is internally consistent across the quarter, the year-to-date window, and the cash-flow line, with no contradicting point inside the filing evidence to flag here.

Scenario analysis

- Reported actuals already sit above the prior year on both headings, forming a credible central case that travel continues in the same direction into the next reporting window. - The base case reads the three-month print as a continuation of the same trend, with revenue and net income each higher than the prior-year quarters the filing compares against. - The half-year window tells the same story across two stacked quarters, so the base path does not require a one-quarter anomaly to fade; it simply persists. - Management's tone in the filing does not flag a reversal, which keeps the central case near the actual reported run-rate rather than at a discount to it.

- Higher revenue sustains a higher net income result, and management's commentary around new programs and capacity ramps (referenced in the MD&A discussion carried forward from the filing) does not contradict that path. - A stronger-than-modeled ramp can lift the top line enough that any unmodeled mix improvement accrues largely to operating income, given the operating leverage the half-year results already exhibit. - The Marle and DAS Medical contingent consideration milestones, which the cited note reports as not currently recognizing a fair-value liability, leave room for a release of that accrual if the entities beat their financial thresholds downstream.

- The contingent consideration narrative also defines the downside on the cost side: if the acquired entities underperform against their EBITDA targets, the existing accruals could grow rather than release, and the acquired businesses may not deliver the revenue ramp this scenario assumes. - The cited note specifically states that the Welch contingent consideration carries no fair value because Welch did not achieve its EBITDA targets for the cited years, and that the Company has also determined it is not probable that Welch will achieve the next year's threshold — a concrete operational miss already disclosed inside the filing. - A demand-led pullback in the bag and specialty components end-markets the Company serves would compress the revenue line, and the half-year's higher operating income would reverse on the way down. - Lower volume would also expose the loss-allowance methodology the filing describes, in which accounts receivable adequacy is sensitive to customer financial condition and the macroeconomic environment; a deterioration on either variable is a downside channel the filing itself identifies.

Counter-evidence and unknowns: - The filing's revenue-disaggregation note acknowledges that warranty activities are not treated as a separate performance obligation, which is a presentation choice rather than a performance argument; it neither confirms nor weakens the upside path. The filing evidence does not attribute this change to any single cause. - The fair-value hierarchy language for the lower fair-value tier (Level 3) explicitly relies on management's best estimate of what market participants would use, so any contingent-consideration re-measurement under either scenario is inherently model-driven rather than market-priced. The filing evidence does not attribute this change to any single cause. - The filing does not provide a forward revenue or earnings guide, so the upside and downside paths here are conditional paths rather than management forecasts. The filing evidence does not attribute this change to any single cause. - The cited disclosure note groups segment-level commentary at a high level only, leaving the segment mechanics behind each scenario partly under-specified. The filing evidence does not disclose segment-level detail for this dimension. - No peer comparison is provided in the filing, so the magnitude of any move cannot be benchmarked against a sector cohort. The filing evidence contains no peer or industry comparison. - Readers comparing this read-through with prior Lizely Finance earnings notes — for example, REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing — should treat the directional parallels cautiously, since the underlying mix and end-market exposure are not the same.

Risks and what to watch

- Reported facts: across the 10-Q for period-ended-2026-06-30, UFP TECHNOLOGIES INC (ticker UFPT, CIK 0000914156, accession 0001628280-26-054428) reported $20,851,000 USD of profit for the three months ended June 30, 2026 and $38,346,000 USD of profit for the six months ended June 30, 2026, with revenue of $173,964,000 USD for the three months and $328,166,000 USD for the six months. The prior comparatives were $17,180,000 USD and $151,176,000 USD for the three months ended June 30, 2025, and $34,364,000 USD and $299,324,000 USD for the six months ended June 30, 2025.

- Management explanations: the filing narrative discusses goodwill-contingent consideration for the Welch, Marble and DAS Medical acquisitions, describing the fair-value hierarchy under Level 1, Level 2 and Level 3, and noting that the Welch contingent consideration carries no fair value as of June of the reporting year because Welch did not achieve the EBITDA targets for two prior years and is not probable to achieve the next year. The Marble and DAS Medical contingent consideration were noted as omitted in the quoted text.

Allowance policy and hierarchical fair-value disclosures are described within Item 6 / Part I financial statements context, with risk and disclosure cross-references in Item 1A and quantitative/qualitative market-risk discussion in Item 3. - Analyst inference: Welch appears to be the most sensitive embedded earn-out exposure given the multi-year miss, while Marble and DAS Medical remain active contingent-payment arrangements whose settlement is driven by achievement of financial thresholds. Readers comparing this period with others (such as REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing) should treat the year-over-year direction tables as the authoritative comparison.

- Counter-evidence and unresolved items: the company has not separately disclosed segment-level detail in this view, so The filing evidence does not disclose segment-level detail for this dimension. applies; there is no peer or industry comparison in the filing itself, so The filing evidence contains no peer or industry comparison. applies.

The filing evidence does not attribute this change to any single cause. applies to any movement in the headline profit and revenue lines. - Unknowns: the resolution timing and final cash outcome of Welch, Marble and DAS Medical earn-outs, the probability-weighted assumptions management will refresh next period, and any change in the contingent-consideration fair value under the cited note are not stated.

- Metrics to watch next period: confirmation that Welch's contingent consideration remains nil only if EBITDA is again missed, any remeasurement of Marble and DAS Medical contingent consideration under the initial liquefaction phase fair-value process, continued growth in $173,964,000 and $328,166,000 versus the prior-year frames, and the trajectory of $20,851,000 and $38,346,000; legal-proceedings updates under Item 1 and controls review under Item 4 remain in scope, while signatories and exhibits sit under Item 5.